OUTLOOK THERAPEUTICS INC (OTLK)
Outlook Therapeutics, Inc. is a NASDAQ-listed common stock issuer in the healthcare sector focused on biotechnology. The company operates as a clinical-stage biopharmaceutical business developing monoclonal antibody therapies for use in ophthalmic indications. Its lead candidate, ONS-5010, is an ophthalmic bevacizumab formulation being studied in Phase III clinical trials for wet age-related macular degeneration and other retinal diseases. Outlook Therapeutics also has collaboration agreements with Cencora. The company was incorporated in 2010, changed its name from Oncobiologics, Inc. in November 2018, and is based in Iselin, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OTLK
|
$1.32
|
-7.5% Downside
|
Fair
|
$5.50
|
286.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-4.4x
|
-9.2x
|
802.7x
|
258.1 M
|
286.8 M
|
9.5%
|
79.8%
|
-47.6
|
—
|
77.2%
|
